GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · BSE Equity Only

BSE Exchange Filings, Explained Simply

AI-powered plain-English analysis of every important BSE announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Today
—
Total
BSE
Exchange
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Strictly sourced from BSE exchange announcements (equity segment only). We show only material, important filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India exchange announcements. More categories will be added over time.
Ipca Laboratories Ltd
Outcome of Board Meeting
M&A ◆ Monitor Closely LOW RISK
📅 Filed on BSE: 26 Jun 2026, 01:15 PM IST  ·  BSE ID: 9cd12e19-3036-4fb9-8a6c-74cf76187714
View Original BSE Filing (PDF)
💡
In Simple Terms
Ipca Laboratories' board approved merging with Krebs Biochemicals to gain manufacturing capabilities and secure key raw material supply.
🤖 AI Summary
  • Ipca Laboratories' Board approved the Scheme of Amalgamation with Krebs Biochemicals & Industries Ltd.
  • Ipca Laboratories (Transferee) reported Standalone Audited Total Income of Rs. 7431 Crores for FY26.
  • Krebs Biochemicals (Transferor) had Audited Total Income of Rs. 26 Crores for FY26.
  • The Appointed Date for the Amalgamation Scheme is 1st April, 2026.
  • Share exchange ratio: 7 equity shares of Re. 1/- each of Ipca for every 200 shares of Rs. 10/- each of Krebs.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Transferee Company (Ipca) Standalone Audited Total Income (FY26)
Rs. 7431 Crores
Transferor Company (Krebs) Audited Total Income (FY26)
Rs. 26 Crores
🏢 How This Affects the Company
📈
Business Impact
The amalgamation consolidates the pharmaceutical businesses of both entities, increasing the combined entity's business and expanding Ipca's capabilities to include fermentation-based Active Pharmaceutical Ingredients (APIs).
💰
Financial Impact
The merger aims for operational synergies and cost optimization, potentially improving profitability by integrating a loss-making subsidiary with Ipca's financial strength.
⚙️
Operational Impact
Ipca Laboratories gains Krebs Biochemicals' manufacturing facility for fermentation-based APIs, securing an uninterrupted supply of critical ingredients used in Ipca's largest selling formulation and key APIs.
⚠️
Risk Impact
The merger mitigates supply chain risks for critical fermentation-based APIs and drug intermediates, ensuring continuity for Ipca's major products.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders; the scheme is subject to regulatory approvals.
👤
Who Is Affected
Shareholders of Krebs Biochemicals will receive 7 equity shares of Re. 1/- each of Ipca Laboratories for every 200 shares of Rs. 10/- each held in Krebs. Ipca shareholders holding Krebs shares will see them cancelled.
🔍
Management Signal
Management intends to consolidate business operations, optimize costs, secure supply chains for key APIs, and leverage Krebs' manufacturing capabilities.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Receipt of necessary approvals under Companies Act, 2013 and SEBI LODR.
Announcement of the record date for share exchange post-approvals.
Financial results post-effective date for operational synergies and cost optimization.
LOW RISK The proposed amalgamation is subject to standard regulatory approvals, a common process for mergers.
💡 Investor Takeaway
Ipca Laboratories' Board approved amalgamating with Krebs Biochemicals & Industries Ltd., which had a Total Income of Rs. 26 Crores for FY26, to Ipca's Rs. 7431 Crores. This aims for operational synergies and secures critical API supply.
⚖️ Strengths & Concerns

✅ Positives

  • Secures uninterrupted supply of fermentation-based API, a key ingredient for Ipca Laboratories' largest selling formulation.
  • Integrates Krebs' fermentation API manufacturing capability, allowing Ipca Laboratories to research, develop, and commercialize new APIs.

⚠️ Concerns

  • Krebs Biochemicals & Industries Ltd. is continuously incurring losses, which Ipca Laboratories will absorb post-amalgamation.
  • The scheme is subject to necessary approvals, and its effective date depends on receiving all consents and approvals.
❓ Frequently Asked Questions
What did Ipca Laboratories' Board approve on June 26, 2026?
Ipca Laboratories' Board approved the Scheme of Amalgamation of Krebs Biochemicals & Industries Ltd. with the company under Sections 230 to 232 of the Companies Act, 2013.
What were the Total Incomes of Ipca Laboratories and Krebs Biochemicals for FY26?
Ipca Laboratories reported a Standalone Audited Total Income of Rs. 7431 Crores for FY26, while Krebs Biochemicals & Industries Ltd. had an Audited Total Income of Rs. 26 Crores for FY26.
What is the share exchange ratio for the Ipca Laboratories and Krebs Biochemicals merger?
The Transferee Company, Ipca Laboratories, shall issue 7 fully paid-up equity shares of Re. 1/- each for every 200 fully paid-up equity shares of Rs. 10/- each held in Krebs Biochemicals.
What is the Appointed Date for the Amalgamation Scheme?
The Appointed Date for the Scheme of Amalgamation is 1st April, 2026.
What is the rationale for the amalgamation of Ipca Laboratories and Krebs Biochemicals?
The rationale includes operational synergies, cost optimization, consolidation of business, reduction of administrative responsibilities, gaining fermentation-based API manufacturing capabilities, and securing uninterrupted supply of critical APIs.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.